Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

LCH-IV, International Collaborative Treatment Protocol för barn och ungdomar med Langerhans cellhistiocytos

9 november 2026 uppdaterad av: North American Consortium for Histiocytosis

The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).

Studieöversikt

Detaljerad beskrivning

The international efforts of the past 20 years have shown that combination therapy with vinblastine and prednisone is an effective therapy for Multi-system (MS)-LCH. The previous prospective trial LCH-III confirmed this regimen as a standard regimen for MS-LCH in patients with and without risk organ involvement. It also showed that prolonged treatment in the latter group (treatment duration of 12 vs. 6 months) is superior in preventing disease reactivations. The results of this trial are encouraging and serve as a basis for the LCH-IV study design.Due to the complexity of the disease presentations and outcomes, the LCH-IV study seeks to tailor treatment based on features at presentation and on response to treatment, leading to seven strata:

  • Stratum I: First-line treatment for MS-LCH patients (Group 1) and patients with Single system (SS)-LCH with multifocal bone or "Central Nervous System (CNS)-risk" lesions (Group 2)
  • Stratum II: Second-line treatment for non-risk patients (patients without risk organ involvement who fail first-line therapy or have a reactivation after completion of first-line therapy)
  • Stratum III: Salvage treatment for risk LCH (patients with dysfunction of risk organs who fail first-line therapy)
  • Stratum IV: Stem cell transplantation for risk LCH (patients with dysfunction of risk organs who fail first-line therapy)
  • Stratum V: Monitoring and treatment of isolated tumorous and neurodegenerative CNS-LCH
  • Stratum VI: Natural history and management of "other" SS-LCH (patients who do not need systemic therapy at the time of diagnosis)
  • Stratum VII: Long-term Follow up (all patients irrespective of previous therapy will be followed for reactivation or permanent consequences once complete disease resolution has been achieved and the respective protocol treatment completed)

Studietyp

Interventionell

Inskrivning (Faktisk)

1400

Fas

  • Fas 2
  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Alabama
      • Birmingham, Alabama, Förenta staterna, 35233
        • Children's of Alabama
    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85006
        • Phoenix Children's Hospital
    • Arkansas
      • Little Rock, Arkansas, Förenta staterna, 72202
        • Arkansas Children's Hospital
    • California
      • Los Angeles, California, Förenta staterna, 90027
        • Children's Hospital of Los Angeles
      • Madera, California, Förenta staterna, 93636
        • Valley Children's Healthcare
      • Oakland, California, Förenta staterna, 94609
        • UCSF Benioff Children's Hospital of Oakland
      • Orange, California, Förenta staterna, 92868
        • Children's Hospital of Orange County
      • San Francisco, California, Förenta staterna, 94158-0106
        • UCSF Helen Diller Family Cancer Center
    • Connecticut
      • Hartford, Connecticut, Förenta staterna, 06106
        • Connecticut Children's Medical Center
    • District of Columbia
      • Washington D.C., District of Columbia, Förenta staterna, 20010
        • Children's National Medical Center
    • Florida
      • St. Petersburg, Florida, Förenta staterna, 33701
        • Johns Hopkins All Children's Hospital
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30342
        • Children's Healthcare of Atlanta, Emory
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611-2991
        • Ann & Robert H. Lurie Children's Hospital of Chicago
    • Indiana
      • Indianapolis, Indiana, Förenta staterna, 46202
        • Riley Hospital for Children - Indiana University
    • Kansas
      • Kansas City, Kansas, Förenta staterna, 64108
        • Children's Mercy Hospitals
    • Kentucky
      • Lexington, Kentucky, Förenta staterna, 40536
        • University of Kentucky A.B.Chandler Medical Center
      • Louisville, Kentucky, Förenta staterna, 40202
        • University of Louisville, Norton Children's Hospital
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21287
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Förenta staterna, 02115
        • Dana Farber Cancer Institute
    • Minnesota
      • Minneapolis, Minnesota, Förenta staterna, 55404
        • Children's Minnesota
    • New Jersey
      • Hackensack, New Jersey, Förenta staterna, 07601
        • Hackensack University Medical Center
    • New York
      • New Hyde Park, New York, Förenta staterna, 11040
        • Cohen Children's Medical Center
      • New York, New York, Förenta staterna, 10029
        • Mount Sinai Hospital
      • New York, New York, Förenta staterna, 10032
        • Columbia University / Herbert Irving Cancer Center
      • New York, New York, Förenta staterna, 10170
        • Memorial Sloan Kettering Cancer Center
      • Syracuse, New York, Förenta staterna, 13210
        • SUNY Upstate Medical University
      • The Bronx, New York, Förenta staterna, 10467
        • Children's Hospital at Montefiore
    • North Carolina
      • Charlotte, North Carolina, Förenta staterna, 28203
        • Carolinas Medical Center, Levine Children's Hospital
    • Ohio
      • Akron, Ohio, Förenta staterna, 44308
        • Akron Children's Hospital
      • Cincinnati, Ohio, Förenta staterna, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Förenta staterna, 44106
        • Rainbow Babies & Children's Hospital, University Hospitals
      • Toledo, Ohio, Förenta staterna, 43606
        • Russell J Ebeid Children's Hospital (Promedica)
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Förenta staterna, 15224
        • UPMC Children's Hospital of Pittsburgh
    • South Carolina
      • Charleston, South Carolina, Förenta staterna, 29425
        • Medical University of South Carolina (MUSC)
      • Greenville, South Carolina, Förenta staterna, 29605
        • Greenville Health System BI-LO Charities Children's Cancer Center
    • Tennessee
      • Memphis, Tennessee, Förenta staterna, 38105
        • St. Jude Children's Research Hospital
      • Nashville, Tennessee, Förenta staterna, 37232
        • Vanderbilt-Ingram Cancer Center
    • Texas
      • Dallas, Texas, Förenta staterna, 75235
        • Children's Medical Center Dallas, UT Southwestern
    • Washington
      • Spokane, Washington, Förenta staterna, 99204
        • Providence Sacred Heart Children's Hospital
      • Tacoma, Washington, Förenta staterna, 98431
        • Madigan Army Medical Center
    • Wisconsin
      • Madison, Wisconsin, Förenta staterna, 53792
        • American Family Children's Hospital University of Wisconsin

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

Inte äldre än 18 år (Barn, Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Stratum I

    • Patients must be less than 18 years of age at the time of diagnosis.
    • Patients must have histological verification of the diagnosis of Langerhans cell histiocytosis according to the criteria described in Section 6.1
    • Signed informed consent form
  • Stratum II

    • Patients of Stratum I who have:
    • Progressive disease (AD worse) in non-risk organs after 6 weeks (Initial Course
    • AD intermediate or worse in non-risk organs or AD better in risk organs after 12 weeks (Initial Course 2)
    • Disease progression (AD worse) in non-risk organs at any time during continuation treatment
    • Active disease at the end of Stratum I treatment
    • Disease reactivation in non-risk organs at any time after completion of Stratum I treatment
  • Stratum III

    • Patients from Stratum I who fulfill the following criteria:

    • AD worse in risk organs after week 6 (after Initial Course 1), or AD worse or AD intermediate in risk organs after week 12 (after Initial Course 2).

    • Presence of unequivocally severe organ dysfunction at the above mentioned evaluation points (hematological dysfunction, liver dysfunction, or both of them) as

      • Hb <70 g/L (<7.0 g/dl) and/or transfusion dependency
      • PLT <20 x109/L (20,000/μL) and/or transfusion dependency (both criteria have to be fulfilled) AND/OR
      • Liver dysfunction (or digestive involvement with protein loss)
      • Total protein <55 g/L or substitution dependency
      • Albumin <25 g/L or substitution dependency (at least one of the two criteria to be fulfilled)
  • Stratum IV

    • Patients from Stratum I or Stratum III who fulfill the following criteria:
    • AD worse in risk organs after week 6 (after Initial Course 1), or AD worse or AD intermediate in risk organs after week 12 (after Initial Course 2) of Stratum I OR
    • AD worse after the 2nd and 3rd 2-CdA/Ara-C course, and those AD worse or AD intermediate after the 4th 2-CdA/Ara-C course of Stratum III AND
    • Presence of unequivocally severe organ dysfunction at the above mentioned evaluation points (hematological dysfunction, liver dysfunction, or both of them) as defined in Table XI (see Section 10.3.1).
    • Informed consent: All patients or their legal guardians (if the patient is <18 years of age) must sign an Ethics or institutional Review Board approved consent form indicating their awareness of the investigational nature and the risks of this study. When appropriate, younger patients will be included in all discussions in order to obtain assent.
    • Adequate organ function: Patients should have adequate hepatic, renal, cardiac and pulmonary function to undergo reduced intensity HCT based upon local institutional guidelines, or at a minimum meet requirements noted in eligibility checklist Appendix A-VIII_1. However, significant hepatic and pulmonary dysfunction, if secondary to underlying LCH disease activity, will not exclude patients from protocol enrollment and should be discussed with the National PI Coordinator and the Coordinating Principal Investigator.
  • Stratum V

    • All patients with verified diagnosis of LCH and MRI findings consistent with ND-CNSLCH irrespective of previous treatments (also those not registered to other Strata ofLCH-IV).
    • Patients with isolated tumorous CNS-LCH (including isolated DI with mass lesion in the hypothalamus-pituitary axis). In patients with already established diagnosis of LCH and radiologic finding of CNS lesions compatible with LCH, a biopsy of the lesion is not obligatory. In all other cases a biopsy of the lesion is needed for inclusion into the study
  • Stratum VI

    -- Patients with newly diagnosed SS-LCH and localization other than "multifocal bone",isolated tumorous CNS lesion, or isolated "CNS-risk" lesion.

  • Stratum VII -- All patients registered in LCH IV (regardless of treatment) as long as consent for longterm follow-up has not been withheld.

Exclusion Criteria:

  • Stratum I

    • Pregnancy (patients of child-bearing age must be appropriately tested before chemotherapy)
    • LCH-related permanent consequences (e.g. vertebra plana, sclerosing cholangitis, lung fibrosis, etc.) in the absence of active disease
    • Prior systemic therapy
  • Stratum II

    • Patients with progressive disease in risk organs
    • Permanent consequences (e.g. sclerosing cholangitis, lung fibrosis, etc.) without evidence of active LCH in the same organ or in any other locations
    • No written consent of the patient or his/her parents or legal guardian
  • Stratum III

    • The presence of any of the following criteria will exclude the patient from the study:
    • Isolated sclerosing cholangitis without evidence of active hepatic LCH as the only evidence of risk organ involvement.
    • Inadequate renal function as defined by serum creatinine > 3x normal for age
  • Stratum IV

    • Pulmonary failure (requiring mechanical ventilation) not due to active LCH.
    • Isolated liver sclerosis or pulmonary fibrosis, without active LCH.
    • Uncontrolled active life-threatening infection.
    • Decreased renal function with a GFR of less than 50ml/1.73m2/min.
    • Pregnancy or active breast feeding
    • Failure to provide signed informed consent
  • Stratum VI

    • Patients with SS-LCH who have an isolated tumorous CNS lesion (they are eligible for Stratum V),
    • Patients with isolated "CNS-risk" or multifocal bone lesions (they are eligible for Stratum I, Group 2)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Stratum I

Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV).

Further therapy prolongation (12 vs. 24 months) and intensification (± mercaptopurine) will further reduce the reactivation rate and the permanent consequences.

Stratum I

Stratum I

Andra namn:
  • Velban®
  • Vincaleukoblastinsulfat

Stratum I

Andra namn:
  • -Purinethol®
  • -6 MP
Experimentell: Stratum II

A uniform "intensive" 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms "INDOMETHACIN" and "6-MP/MTX" (mercaptopurine and Methotrexate).

Andra namn:
  • Cytarabin, Ara-C

Stratum I

Stratum I

Andra namn:
  • Velban®
  • Vincaleukoblastinsulfat

Stratum I

Andra namn:
  • -Purinethol®
  • -6 MP

Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.

fixed dose weekly orally for total treatment duration of 24 months.

Experimentell: Stratum III

Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy.

The initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum.

Andra namn:
  • Leustatin®
  • 2-CdA
  • Cladribin®
Experimentell: Stratum IV

To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III).

Experimentell: Stratum V

Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH

- Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice.

Andra namn:
  • Cytarabin, Ara-C
Andra namn:
  • Leustatin®
  • 2-CdA
  • Cladribin®
Andra namn:
  • IVIG
Experimentell: Stratum VI

Natural history and management of "other" SS-LCH not eligible for stratum I group 2.

  • Treatment Options- Management (mostly "wait & see" and topical treatment) is left to the discretion of the treating physician. All treatments and disease responses must be reported in the database. In the case of uncertainties please contact your National Coordinator.
  • Patients being followed on Stratum VI who have progression of disease to MSLCH, multifocal bone disease or CNS-risk bone lesions should be enrolled on Stratum I therapy.
  • Patients being followed on Stratum VI who develop isolated tumorous or neurodegenerative CNS-LCH should be enrolled on Stratum V.
Andra namn:
  • Cytarabin, Ara-C
Andra namn:
  • Leustatin®
  • 2-CdA
  • Cladribin®
Andra namn:
  • IVIG

Stratum I

Stratum I

Andra namn:
  • Velban®
  • Vincaleukoblastinsulfat

Stratum I

Andra namn:
  • -Purinethol®
  • -6 MP

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of Patients with Reactivation Free Survival
Tidsram: 12 Months

Stratum I, II, VI

12 Months
Response Rate of Second Cycle
Tidsram: 9 weeks

Stratum III

9 weeks
Overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT)
Tidsram: 3 Years

Stratum IV

3 Years
The cumulative incidence of radiological and clinical neurodegeneration in patients with isolated tumorous CNS-LCH, DI, anterior pituitary dysfunction, and those with CNS-risk lesions
Tidsram: 2 Years

Stratum V

2 Years
The time interval and cumulative incidence of progression of radiological neurodegeneration to clinically manifested ND-CNS-LCH
Tidsram: 2 Years

Stratum V

2 Years
Cumulative incidence of specific Permanent Consequences e.g. diabetes insipidus (DI), growth hormone deficiency (GHD), neuropsychological impairment, etc.
Tidsram: 2 Years

From all treatment stratum via long-term follow up in Stratum VII

2 Years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Antal deltagare med allvarliga och icke-allvarliga biverkningar
Tidsram: 2 år
2 år
Kumulativ förekomst av reaktiveringar i riskorgan
Tidsram: 2 år
2 år
Incidens av hematopoetisk återhämtning och donatorchimerism vid d+100 och 1 år efter RIC-HSCT
Tidsram: 2 år
2 år
Identifiera möjliga riskfaktorer för permanenta konsekvenser (PC)
Tidsram: 2 år
2 år
Overall Survival
Tidsram: 2 Years

Stratum I

2 Years
Incidence of Permanent Consequences
Tidsram: 2 Years

All Stratum

2 Years
Time to complete disease resolution
Tidsram: 2 Years

Stratum III

2 Years
Response rate to the combination of prednisone, vincristine and cytarabine
Tidsram: 2 years

Stratum II

2 years
The proportion of patients alive and free of disease without permanent consequences (e.g. diabetes insipidus, anterior pituitary dysfunction, radiological or clinical neurodegeneration)
Tidsram: 2 Years

Stratum II

2 Years
Percentage of treatment-related toxicities
Tidsram: 2 Years

Stratum II

2 Years
Reactivation rates after continuation treatment with Indomethacin vs. 6-MP/MTX.
Tidsram: 2 years

Stratum II

2 years
The type of subsequent intensive and/or maintenance therapy utilized
Tidsram: 2 Years

Stratum III

2 Years
Early and late mortality
Tidsram: 2 Years

Stratum II

2 Years
Early and late toxicity
Tidsram: 2 Years

Stratum III

2 Years
d+100 transplant related mortality
Tidsram: 2 Years

Stratum IV

2 Years
Record all occurrence of skin, GI or liver abnormalities fulfilling criteria of Grades II-IV acute GVHD
Tidsram: 2 Years

Stratum IV: Hematopoetic Stem Cell Transplantation for Risk LCH

2 Years
Percentage of Participants with incidence of chronic GVHD
Tidsram: 2 Years

Stratum IV

2 Years
Response Rate to ND-CNS-targeted therapy at 12 and 24 months after start of therapy
Tidsram: 2 years

Stratum V

2 years
Response of isolated tumorous CNS-LCH to 2-CDA
Tidsram: 2 Years

Stratum V

2 Years
Frequency of ND-CNS-LCH in patients with isolated tumorous CNS-LCH
Tidsram: 2 Years

Stratum V

2 Years
Methods of early identification of ND-CNS-LCH
Tidsram: 2 Years

Stratum V - Exploration of the value of neurochemistry, neurophysiology, and neuropsychology methods in early identification of ND-CNS-LCH and in assessing its severity, and comparison to MRI findings.

2 Years
Need for systemic therapy later during disease course
Tidsram: 2 Years

Stratum VI

2 Years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Studiestol: Milen Minkov, MD, Ph.D, Children's Cancer Research Institute / St. Anna Children's Hospital
  • Studiestol: Carlos Rodriguez-Galindo, MD, North American Consortium for Histiocytosis

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

2 november 2016

Primärt slutförande (Beräknad)

1 november 2031

Avslutad studie (Beräknad)

1 november 2031

Studieregistreringsdatum

Först inskickad

7 juli 2014

Först inskickad som uppfyllde QC-kriterierna

30 juli 2014

Första postat (Beräknad)

31 juli 2014

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

10 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera